A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Clinical trial NCT04129996 · UNKNOWN
Trial details
- NCT number
- NCT04129996
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-01
- Primary completion
- 2022-09-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.